p.106 抽出テキスト

513. Ferrari R, Camici PG, Crea F, Danchin N, Fox K, Maggioni AP, et al. Expert consensus document: a ‘diamond’ approach to personalized treatment of angina. Nat Rev Cardiol 2018;15:120–32. https://doi.org/10.1038/nrcardio.2017.131 514. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/ AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60:e44–164. https://doi.org/10.1016/j.jacc.2012.07.013 515. Manolis AJ, Boden WE, Collins P, Dechend R, Kallistratos MS, Lopez Sendon J, et al. State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. Eur J Intern Med 2021;92:40–7. https://doi.org/10.1016/j.ejim.2021.08. 003 516. Bertero E, Heusch G, Munzel T, Maack C. A pathophysiological compass to personalize antianginal drug treatment. Nat Rev Cardiol 2021;18:838–52. https://doi.org/10. 1038/s41569-021-00573-w 517. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetière P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005;352:1951–8. https://doi.org/10.1056/NEJMoa043012 518. Shu DF, Dong BR, Lin XF, Wu TX, Liu GJ. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Prev Cardiol 2012;19:330–41. https://doi.org/ 10.1177/1741826711409325 519. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730–7. https://doi.org/10.1136/bmj.318.7200.1730 520. Martínez-Milla J, Raposeiras-Roubín S, Pascual-Figal DA, Ibáñez B. Role of betablockers in cardiovascular disease in 2019. Rev Esp Cardiol (Engl Ed) 2019;72: 844–52. https://doi.org/10.1016/j.rec.2019.04.014 521. Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, et al. Effect of oral beta-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2019;5:12–20. https://doi.org/10.1093/ehjcvp/pvy034 522. Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabés JA, Sánchez PL, et al. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). Eur Heart J Cardiovasc Pharmacother 2022;8:291–301. https://doi.org/10. 1093/ehjcvp/pvab060 523. Raposeiras-Roubín S, Abu-Assi E, Redondo-Diéguez A, González-Ferreiro R, López-López A, Bouzas-Cruz N, et al. Prognostic benefit of beta-blockers after acute coronary syndrome with preserved systolic function. Still relevant today? Rev Esp Cardiol (Engl Ed) 2015;68:585–91. https://doi.org/10.1016/j.rec.2014.07.028 524. Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, et al. β-Blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol 2017;69:2710–20. https://doi.org/10.1016/j.jacc.2017. 03.578 525. Kim J, Kang D, Park H, Kang M, Park TK, Lee JM, et al. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J 2020;41:3521–9. https://doi.org/10.1093/eurheartj/ ehaa376 526. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–726. https:// doi.org/10.1093/eurheartj/ehab368 527. Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One 2018;13:e0199347. https://doi.org/10.1371/journal.pone.0199347 528. Munkhaugen J, Ruddox V, Halvorsen S, Dammen T, Fagerland MW, Hernæs KH, et al. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): rationale and design of a prospective, randomized, open, blinded end point study. Am Heart J 2019;208: 37–46. https://doi.org/10.1016/j.ahj.2018.10.005 529. Kristensen AMD, Bovin A, Zwisler AD, Cerquira C, Torp-Pedersen C, Bøtker HE, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials 2020;21:415. https://doi.org/10.1186/s13063-020-4214-6 530. Yndigegn T, Lindahl B, Alfredsson J, Benatar J, Brandin L, Erlinge D, et al. Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI). Eur Heart J Cardiovasc Pharmacother 2023;9: 192–7. https://doi.org/10.1093/ehjcvp/pvac070 531. Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascular drugs: challenges for research and for patient care. J Am Coll Cardiol 2015;66:1273–85. https://doi.org/10. 1016/j.jacc.2015.07.018 532. Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, et al. β Blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016;354:i4801. https://doi.org/10.1136/bmj.i4801 533. Ishak D, Aktaa S, Lindhagen L, Alfredsson J, Dondo TB, Held C, et al. Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes. Heart 2023;109:1159–65. https://doi.org/10.1136/heartjnl-2022-322115 534. Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of beta-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases. Circ Cardiovasc Qual Outcomes 2018;11:e004356. https://doi.org/10.1161/CIRCOUTCOMES.117.004356 535. Zeitouni M, Kerneis M, Lattuca B, Guedeney P, Cayla G, Collet J-P, et al. Do patients need lifelong β-blockers after an uncomplicated myocardial infarction? Am J Cardiovasc Drugs 2019;19:431–8. https://doi.org/10.1007/s40256-019-00338-4 536. van de Ven LL, Vermeulen A, Tans JG, Tans AC, Liem KL, Lageweg NC, et al. Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates. Int J Cardiol 1995;47:217–23. https://doi.org/10.1016/0167-5273(94)02194-n 537. Ueberbacher HJ, Patyna WD, Krepp P, Puespoek J, Neuhaus R, Hilbich K, et al. [Randomized, double-blind comparison of isosorbide-5-mononitrate and delayed-action nifedipine in patients with stable exertional angina. Multicenter Study Group]. Schweiz Med Wochenschr 1991;121:1836–40. 538. Davies RF, Habibi H, Klinke WP, Dessain P, Nadeau C, Phaneuf DC, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. J Am Coll Cardiol 1995;25:619–25. https://doi.org/10. 1016/0735-1097(94)00436-t 539. Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. Coron Artery Dis 2002;13:427–36. https://doi.org/10.1097/00019501-200212000- 00008 540. Wei J, Wu T, Yang Q, Chen M, Ni J, Huang D. Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials. Int J Cardiol 2011;146:4–12. https://doi.org/10.1016/j.ijcard.2010.05.019 541. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817–21. https://doi.org/10.1016/s0140-6736(08)61171-x 542. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30: 2337–45. https://doi.org/10.1093/eurheartj/ehp358 543. Jiang J, Li Y, Zhou Y, Li X, Li H, Tang B, et al. Oral nicorandil reduces ischemic attacks in patients with stable angina: a prospective, multicenter, open-label, randomized, controlled study. Int J Cardiol 2016;224:183–7. https://doi.org/10.1016/j.ijcard.2016.08.305 544. Horinaka S, Yabe A, Yagi H, Ishimitsu T, Yamazaki T, Suzuki S, et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2010;74:503–9. https://doi.org/10. 1253/circj.cj-09-0649 545. Zhu WL, Shan YD, Guo JX, Wei J-P, Yang X-C, Li T-D, et al. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J 2007;71: 826–33. https://doi.org/10.1253/circj.71.826 546. IONA study group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359: 1269–75. https://doi.org/10.1016/s0140-6736(02)08265-x 547. Di Somma S, Liguori V, Petitto M, Carotenuto A, Bokor D, de Divitiis O, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993;7:119–23. https://doi.org/10.1007/BF00878320 548. Döring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992;20 Suppl 3:S74–81. https://doi.org/10.1097/00005344- 199206203-00013 549. Zhao Y, Peng L, Luo Y, Li S, Zheng Z, Dong R, et al. Trimetazidine improves exercise tolerance in patients with ischemic heart disease: a meta-analysis. Herz 2016;41: 514–22. https://doi.org/10.1007/s00059-015-4392-2 550. Peng S, Zhao M, Wan J, Fang Q, Fang D, Li K. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol 2014;177: 780–5. https://doi.org/10.1016/j.ijcard.2014.10.149 551. Beltrame JF. Ivabradine and the SIGNIFY conundrum. Eur Heart J 2015;36:3297–9. https://doi.org/10.1093/eurheartj/ehv368 552. Dittrich H, Henneke KH, Pohlmann M, Pongratz G, Bachmann K. Provocation of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Downloaded from academic.oup.com/eurheartj/article/45/36/3415/7743115 by guest on 07 October 2026